Carlos Domínguez-Massa

Dr. Carlos Domínguez-Massa

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
CDCarlos Domínguez-Massa
Carlos Domínguez-Massa
LDLucía Doñate-Bertolín
Lucía Doñate-Bertolín
ÓBÓscar R. Blanco-Herrera
Óscar R. Blanco-Herrera
THTomás Heredia-Cambra
Tomás Heredia-Cambra
MPManuel Pérez-Guillén
Manuel Pérez-Guillén
FHFernando Hornero-Sos
Fernando Hornero-Sos
Inflammatory myofibroblastic tumor is a neoplasm with uncertain behavior. We describe a case in a 66-year-old female who underwent resection of a left atrial tumor suspected to be a cardiac myxoma which was subsequently diagnosed as an inflammatory myofibroblastic tumor. After three years' follow-up the patient underwent a second operation to remove tumoral occurrence in the right atrium, diagnosed as an intimal sarcoma. It cannot be confirmed whether the tumoral recurrence with a different diagnosis (intimal sarcoma) was a progression from the primary tumor or the metachronous appearance of a spontaneous sarcoma.

1 October 2019 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
CDCarlos Domínguez-Massa
Carlos Domínguez-Massa
ABAlberto Berbel-Bonillo
Alberto Berbel-Bonillo
MPManuel Pérez-Guillen
Manuel Pérez-Guillen
JMJosé A. Montero-Argudo
José A. Montero-Argudo
Aberrant right subclavian artery is the most frequent anomaly of the aortic arch, and in 60% of cases is associated with Kommerell diverticulum. It is usually asymptomatic but may present with dysphagia or asthma due to esophageal and tracheal compression. Indications for surgical repair have not been established; however, when Kommerell diverticulum is complicated by aortic dissection the treatment is surgery. We present the case of a 54-year-old man with thoracic pain due to dissection of an aberrant right subclavian artery associated with Kommerell diverticulum. Elective surgical treatment was performed.

9 May 2025 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
CDCarlos Domínguez-Massa
Carlos Domínguez-Massa
MPManuel Pérez-Guillén
Manuel Pérez-Guillén
IZIratxe Zarragoikoetxea-Jauregui
Iratxe Zarragoikoetxea-Jauregui
ETEduardo Tébar-Botí
Eduardo Tébar-Botí
STSalvador Torregrosa-Puerta
Salvador Torregrosa-Puerta
JMJuan Bautista Martínez-León
Juan Bautista Martínez-León

16 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
RVRaquel López Vilella
Raquel López Vilella
MGManuel Pérez Guillén
Manuel Pérez Guillén
BCBorja Guerrero Cervera
Borja Guerrero Cervera
RCRicardo Gimeno Costa
Ricardo Gimeno Costa
IZIratxe Zarragoikoetxea
Iratxe Zarragoikoetxea
Luís Almenar-BonetLuís Almenar-Bonet
Luís Almenar-Bonet
Background/Objectives: The direct bridge to urgent heart transplant (HT) with venoarterial extracorporeal membrane oxygenation (VA-ECMO) support has been associated with high morbidity and mortality. The objective of this study is to analyze the morbidity and mortality of patients transplanted with VA-ECMO and compare the presumed differences between various eras over a 17-year timeline. Methods: This is a prospective, observational study on consecutive patients stabilized with VA-ECMO and transplanted with VA-ECMO from July 2007 to December 2023 at a reference center (98 patients). Objective variables were mortality and morbidity from renal failure, venous thromboembolic disease (VTD), primary graft dysfunction (PGD), the need for tracheostomy, severe myopathy, reoperation, post-transplant ECMO, vascular complications, and sepsis/infection. Results: The percentage of patients who reached transplantation without the need for mechanical ventilation has increased over the periods studied. No significant differences were found between the study periods in 30-day mortality (p = 0.822), hospital discharge (p = 0.972), one-year mortality (p = 0.706), or five-year mortality (p = 0.797). Survival rates in these periods were 84%, 75%, 64%, and 61%, respectively. Comorbidities were very frequent, with an average of 3.33 comorbidities per patient. The most frequent were vascular complications (58%), the need for post-transplant ECMO (57%), and myopathy (55%). The development of myopathy and the need for post-transplant ECMO were higher in recent periods (p = 0.004 and p = 0.0001, respectively). Conclusions: VA-ECMO support as a bridge to HT allows hospital discharge for 3 out of 4 transplanted patients. This survival rate has not changed over the years. The comorbidities associated with this device are frequent and significant.

1 April 2018 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
CDCarlos Domínguez-Massa
Carlos Domínguez-Massa
ABAna M. Bel-Minguez
Ana M. Bel-Minguez
MPManuel Perez-Guillen
Manuel Perez-Guillen
ABAlberto Berbel-Bonillo
Alberto Berbel-Bonillo
FHFernando Hornero-Sos
Fernando Hornero-Sos

14 October 2018 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
CDCarlos Domínguez-Massa
Carlos Domínguez-Massa
FSFélix Serrano-Martínez
Félix Serrano-Martínez
ÓBÓscar R. Blanco-Herrera
Óscar R. Blanco-Herrera
ABAlberto Berbel-Bonillo
Alberto Berbel-Bonillo
FHFernando Hornero-Sos
Fernando Hornero-Sos
JMJosé A. Montero-Argudo
José A. Montero-Argudo
Thorough study is required to decide the appropriate management of hepatic tumors in children. We present a case report of a hepatic embryonal undifferentiated sarcoma with unfavorable prognosis in a nine-year-old girl. After undergoing a detailed cancer characteristics and extension study, a two-stage surgery approach was decided. The hepatic tumor resection was the first procedure to be performed. One week later, under cardiopulmonary bypass, deep hypothermia, and circulatory arrest, thrombectomy of the inferior vena cava and right atrium was accomplished, plus thromboendarterectomy of the right pulmonary artery. During a four-year follow-up, the patient continues to be disease-free.